2014


To access this material please log in or register

Register Authorize
2014/№4

Incidence of polymorphous markers for АСЕ (I/D), AGT (M235T), and ADRB2 (Q27E, G16R) genes associated with risk for development of cardiovascular diseases in patients with CHF

Krasnova O. A., Sitnikova M. Yu.
Federal State Budgetary Institution, “North-West Federal Medical Research Center” of the RF Ministry of Health Care, Akkuratova 2, St.-Petersburg 197341

Keywords: gene polymorphism, cardiovascular diseases, CHF


DOI: 10.18087/rhfj.2014.4.1941

Background. CHF is a multi-factor disease where both external and genetic factors contribute to the CHF pathogenesis. The renin-angiotensin-aldosterone system (RAAS) and the sympathetico-adrenal system (SAS) are the major systems participating in the pathogenesis of CHF. Studying effects of gene polymorphism for both individual systems and their combinations may accelerate development of efficient prevention and improve the quality of predicting a possible disease. Aim. To study patterns of allele combinations associated with increased risk for cardiovascular diseases (CVD), polymorphous markers for genes of АСЕ (I / D), angiotensin AGT (M235T), and β2-adrenoceptors ADRB2 (Q27E, G16R) in a group of patients with systolic CHF of ischemic origin as compared to individuals with risk factors (RFs) for CHF. Materials and methods. The study included 234 men residing in St. Petersburg and the Leningrad Region. The main group consisted of 135 men with FC II–IV systolic CHF of ischemic origin. The reference group consisted of 99 men with one or more RFs for CHF. The molecular and genetic study was performed using the PCR method followed by restriction analysis of obtained fragments. Statistical analysis was carried out using the “SPSS” Ver. 15 software. Results. Initially, a group of alleles was selected in this population: allele D of the ACE gene; allele T of the AGT gene; and alleles 27E and 16R of the ADRB2 gene. Then two groups were formed: group 1 reflected the presence of a studied allele without taking into account carriage of homozygotes or heterozygotes; group II reflected incidence of the number of a studied allele. Significant differences in incidences of the studied alleles were not observed in the group of CHF patients. Similar analysis of distribution was performed for patients of the reference group. Patients of this group were divided into two subgroups based on the presence of absence of IHD. Most of the reference group patients without IHD significantly more frequently (χ²=р<0.05; likelihood ratio = 1.27 (1.01–1.62)) were carriers of all four studied alleles in the heterozygous state as compared to patients with IHD and CHF. Conclusion. Patients with RFs for CHF but without IHD more often carry four alleles (D of the АСЕ gene, 235Т of the AGT gene, and 27E and 16R of the ADRB2 gene) in the heterozygous state than patients with IHD and CHF. Incidence of the studied alleles did not significantly differ in the group of patients with systolic CHF of ischemic origin.
  1. Калюжин В. В., Тепляков А. Т., Вечерский Ю. Ю. Патогенез хронической сердечной недостаточности: изменение доминирующей парадигмы. Бюллетень сибирской медицины. 2007;4:71–76.
  2. Шляхто Е. В., Шварц И. Е., Волкова Е. В. и др. I / D полиморфизм ангиотензинпревращающего фермента у мужчин, перенесших инфаркт миокарда в молодом возрасте. Российский физио­логи­ческий журнал. 2001;5:642–648.
  3. Nair KG, Shalia KK, Ashavaid TF, Dalal JJ. Coronary heart disease, hypertension, and angiotensinogen gene variants in Indian population. J Clin Lab Anal. 2003;17 (5):141–6.
  4. Dungan JR, Conley YP, Langaee TY et al. Altered beta-2 adrenergic receptor gene expression in human clinical hypertension. Biol Res Nurs. 2009 Jul;11 (1):17–26.
  5. Kunkel LM, Smith KD, Boyer SH et al. Analysis of human Y-chromosome-specific reiterated DNA in chromosome variants. Proc Natl Acad Sci U S A. 1977 Mar;74 (3):1245–9.
  6. Jeunemaitre X, Lifton RP, Hunt SC et al. Absence of linkage between the angiotensin converting enzyme locus and human essential hypertension. Nat Genet. 1992;1 (1):72–75.
  7. Cambien F, Alhenc-Gelas F, Herbeth B et al. Familial resemblance of plasma angiotensin-converting enzyme level: the Nancy Study. Am J Hum Genet. 1988 Nov;43 (5):774–80.
  8. Sethi AA, Nordestgaard BG, Tybjaerg-Hansen A. Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: a meta-analysis. Arterioscler Thromb Vasc Biol. 2003;23 (7):1269–1275.
  9. Di Pasquale P, Cannizzaro S, Paterna S. Does angiotensin-conver­ting enzyme gene polymorphism affect blood pressure? Findings after 6 years of follow-up in healthy subjects. Eur J Heart Fail. 2004 Jan;6 (1):11–6.
  10. Мелентьев И. А., Вершинин А. А., Колесникова Е. А. и др. Клиническое течение ишемической болезни сердца, постинфарктное ремоделирование, психологический статус и сроки госпитализации у больных с различными генотипами гена ангио­тензинпревращающего фермента. Российский кардиологический журнал. 2006;3:6–16.
  11. Holmer SR, Bickeböller H, Hengstenberg C et al. Angiotensin converting enzyme gene polymorphism and myocardial infarction a large association and linkage study. Int J Biochem Cell Biol. 2003 Jun;35 (6):955–62.
  12. Schut AF, Bleumink GS, Stricker BH et al. Angiotensin converting enzyme insertion / deletion polymorphism and the risk of heart failure in hypertensive subjects. Eur Heart J. 2004 Dec;25 (23):2143–8.
  13. Rodriguez-Perez JC, Rodriguez-Esparragon F, Hernandez-Perera O et al. Association of angiotensinogen M235T and A (-6) G gene polymorphisms with coronary heart disease with independence of essential hypertension: the PROCAGENE study. Prospective Cardiac Gene. J Am Coll Cardiol. 2001;37 (6):1536–1542.
  14. Zakrzewski-Jakubiak M, de Denus S, Dube MP et al. Ten renin-angiotensin system-related gene polymorphisms in maximally treated Canadian Caucasian patients with heart failure. Br J Clin Pharmacol. 2008;65 (5):742–751.
  15. Castellano M, Rossi F, Giacche M et al. Beta2‑adrenergic receptor gene polymorphism, age, and cardiovascular phenotypes. Hypertension. 2003;41 (2):361–7.
  16. Heckbert SR, Hindorff LA, Edwards KL et al. Beta2‑adrenergic receptor polymorphisms and risk of incident cardiovascular events in the elderly. Circulation. 2003;107 (15):2021–2024.
  17. Ларионова В. И. Клинико-генетический анализ предрасположенности к развитию атеросклероза у детей и подростков. Автореф. дисс. докт. наук. – Спб.: 2005. – 25 с.
  18. Хмырова А. П., Войтович А. Н., Богданова М. А. Частота редких аллелей некоторых генов у детей и подростков с отягощенным семейным анамнезом по развитию сердечно-сосудистой патологии. Клинико-лабораторный консилиум. 2010;2–3:83.
Krasnova O.A., Sitnikova M.Yu. Incidence of polymorphous markers for АСЕ (I/D), AGT (M235T), and ADRB2 (Q27E, G16R) genes associated with risk for development of cardiovascular diseases in patients with CHF. Russian Heart Failure Journal. 2014;85 (4):213–217

To access this material please log in or register

Register Authorize
Ru En